UCB raises 2026 guidance: UCB stock gains 4.54 percent

Published on 10/26/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB lifts its 2026 revenue outlook to the low twenties on October 22, 2026. UCB stock costs EUR 275.35, 4.54 percent above its Xetra close.

Guidance and portfolio metrics

UCB raised its 2026 revenue growth outlook to the low twenties on October 22, 2026.
BIMZELX sales reached EUR 1.52 billion in the first half of 2026.
UCB stock trades at EUR 275.35 at 10:21 a.m. CET at Lang & Schwarz on October 26, 2026, 4.54 percent above the Xetra close of October 23, 2026.

Architektur-Render eines geschwungenen Glasgebäudes mit Reflexionsbecken und begrünter Umgebung — UCB S.A. (BE0003739530) symbolisiert durch elegantes Architektur-Render eines modernen Biopharma-Hauptsitzes mit Glasfassade, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) raised its 2026 financial guidance on October 22, 2026, while its stock traded at EUR 275.35 at Lang & Schwarz on October 26, 2026 at 10:21 a.m. CET, up 4.54 percent versus the Xetra close of October 23, 2026 at EUR 263.40. According to MarketScreener, the company now expects revenue growth in the low twenties at constant exchange rates, compared with its previous low- to mid-teens outlook.

Guidance widens the growth gap

The upgrade also moved adjusted EBITDA growth expectations into the low-to-mid forties, from the previous mid-teens to low-twenties range. UCB said stronger performance from BIMZELX in the United States and continued CIMZIA volume growth supported the revision.

The guidance excludes proceeds from the sale of a Priority Review Voucher. UCB said that transaction could add low- to mid-single-digit percentage points to revenue and adjusted EBITDA growth.

What does the portfolio show?

UCB's investor page lists BIMZELX sales of EUR 1.52 billion in the first half of 2026, alongside EUR 954 million for CIMZIA and EUR 239 million for FINTEPLA. The company also reported more than 135,000 BIMZELX patients globally in the first half of 2026. These figures show how heavily the upgraded outlook depends on established medicines rather than a single pipeline milestone.

Analyst expectations also moved into view after the guidance update. Investing.com reported on October 23, 2026 that TD Cowen raised its price target from EUR 305.00 to EUR 340.00 while maintaining a Buy rating. The firm cited a projected EUR 200.00 million improvement in BIMZELX consensus estimates.

Next reporting date

UCB will publish its full-year 2026 results and formal 2027 guidance on February 25, 2027, according to the October 22, 2026 company announcement carried by MarketScreener. That date gives investors the next formal checkpoint for testing whether the higher growth assumptions are translating into reported earnings.

Stock holds a higher valuation level

UCB's current price is 4.54 percent above the Xetra close of October 23, 2026. The move leaves the stock trading above the prior German-market reference level while the business enters the final months of its upgraded 2026 outlook.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.